What is CYBN's current stock price?

CYBN (Cybin Inc.) is currently trading at $8.28 with a market cap of $413.0M.

What sector is Cybin Inc. in?

Cybin Inc. (CYBN) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

Back to Market返回行情

CYBN Cybin Inc.

AMEXHealthcare

$8.28+1.22%ClosedMarket Cap: $413.0M

As of 2026-01-02 16:00

Why CYBN matters now

Cybin Inc. (CYBN) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.28 with +1.22% on the session and $413.0M in market capitalization.

The latest indexable market news headline is "Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies" from Proactive Investors - Finance.

Latest News

Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: JefferiesProactive Investors - Finance · 2026-07-15

CleanSpark shares surge after company secures $6.6B data center lease agreementProactive Investors - Finance · 2026-07-14

Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacityProactive Investors - Finance · 2026-07-14

Cybin: A Speculative Bet On Their Pivotal Depression ReadoutSeeking Alpha · 2026-06-27

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

AMEX

Beta

0.79

Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.